苹果多酚提取物对高脂诱导肝脏SIRT1杂合突变C57BL/6小鼠肝脏脂质组学的影响

马婕妤; 殷焱; 栾文雪; 尚思源; 李新莉

营养学报 ›› 2024, Vol. 46 ›› Issue (6) : 606-611.

论著

马婕妤, 殷焱, 栾文雪, 尚思源, 李新莉

作者信息 +

EFFECTS OF APPLE POLYPHENOLS EXTRACT ON LIVER LIPIDOMICS IN HEPATIC SIRT1 HETEROZYGOUS MUTANT C57BL/6 MICE FED A HIGH-FAT DIET

MA Jie-yu, YIN Yan, LUAN Wen-xue, SHANG Si-yuan, LI Xin-li

Author information +

文章历史 +

摘要

目的探讨苹果多酚提取物（APE）对高脂饮食诱导肝脏SIRT1杂合突变（SIRT1^+/-）C57BL/6小鼠肝脏脂质组学的影响。方法 C57BL/6雄鼠与雌鼠随机分为对照组（WT+HFD）,肝脏SIRT1杂合突变组（SIRT1^+/-+HFD）,肝脏SIRT1杂合突变APE干预组（SIRT1^+/-+HAP）,三组均给予高脂饲料喂养8 w,APE干预组同时给予500 mg/(kg·bw·d)的APE溶液灌胃,每周记录小鼠体重与摄食量变化。采用液相色谱-质谱联用（LC-MS）法检测小鼠肝脏中差异表达的脂质代谢物。结果与WT+HFD组相比,SIRT1^+/-+HFD组中有12种TG类的脂质水平明显升高,而APE干预后下降;除TG 52:4-18:2外,雌性SIRT1^+/-小鼠所有确定的TG种类的含量都明显高于雄性SIRT1^+/-小鼠(P< 0.05),但野生型小鼠之间的脂质特征并无统计学差异。结论 APE干预通过影响脂质代谢组学成分改善高脂诱导的、肝脏SIRT1杂合突变小鼠的肝脏总脂质的变化,且APE干预对SIRT1^+/-雌性小鼠的改善作用优于雄性小鼠。

Abstract

Objective To investigate the effects of apple polyphenol extract (APE) on liver lipidomics in high-fat diet (HFD) fed C57BL/6 mice with hepatic SIRT1 heterozygous mutation (SIRT1^+/-). Methods C57BL/6 male and female mice were randomly divided into control group (WT+HFD), SIRT1 heterozygous mutation group (SIRT1^+/-+HFD), and SIRT1 heterozygous mutation with APE intervention group (SIRT1^+/-+HAP). All mice were fed HFD for 8 consecutive weeks, and mice in SIRT1^+/-+HAP group were gavaged with 500 mg/(kg·bw·d) APE solution. Body weight and food intake were recorded every week. The hepatic lipid metabolites were detected by a liquid chromatograph-mass spectrometer (LC-MS). Results Significantly increased contents of 12 TG species in the SIRT1^+/-+HFD group were observed compared with the WT+HFD group, which were decreased after APE intervention. Except TG 52:4-18:2, female SIRT1^+/- mice had significantly higher levels of all identified TG species than male SIRT1^+/- mice（P<0.05）, but there was no significant difference in lipid profiles between the WT groups. Conclusion APE intervention improves hepatic lipids in HFD exposed SIRT1^+/- mice by regulating lipid metabolomics, and the ameliorated effects of APE on hepatic lipids are better in SIRT1^+/- female mice than in male mice.

导出引用

马婕妤, 殷焱, 栾文雪, 尚思源, 李新莉. 苹果多酚提取物对高脂诱导肝脏SIRT1杂合突变C57BL/6小鼠肝脏脂质组学的影响[J]. 营养学报. 2024, 46(6): 606-611

MA Jie-yu, YIN Yan, LUAN Wen-xue, SHANG Si-yuan, LI Xin-li. EFFECTS OF APPLE POLYPHENOLS EXTRACT ON LIVER LIPIDOMICS IN HEPATIC SIRT1 HETEROZYGOUS MUTANT C57BL/6 MICE FED A HIGH-FAT DIET[J]. Acta Nutrimenta Sinica. 2024, 46(6): 606-611

中图分类号： R151.2

参考文献

[1] Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10739 607 individuals[J]. J Clin Endocrinol Metab,2022, 107: 2691–2700.
[2] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology,2018, 67: 123–133.
[3] Wang X, Shi L, Wang X, et al. MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis[J]. Int J Biol Macromol, 2019, 141: 1013–1021.
[4] Smeriglio A, Barreca D, Bellocco E, et al. Chemistry, pharmacology and health benefits of anthocyanins[J].Phytother Res, 2016, 30: 1265–1286.
[5] Moreau RA, Nyström L, Whitaker BD, et al. Phytosterols and their derivatives: structural diversity, distribution,metabolism, analysis, and health-promoting uses[J].Prog Lipid Res, 2018, 70: 35–61.
[6] Rana A, Samtiya M, Dhewa T, et al. Health benefits of polyphenols: A concise review[J]. J Food Biochem, 2022, 46: e14264.
[7] Toma L, Sanda GM, Niculescu LS, et al. Phenolic compounds exerting lipid-regulatory, anti-inflammatory and epigenetic effects as complementary treatments in cardiovascular diseases[J].Biomolecules,2020,10: 641.
[8] Ren Y, Li S, Song Z, et al. The regulatory roles of polysaccharides and ferroptosis-related phytochemicals in liver diseases[J]. Nutrients,2022, 14: 2303.
[9] Zhang S, Xu M, Zhang W, et al. Natural polyphenols in metabolic syndrome: protective mechanisms and clinical applications[J]. Int J Mol Sci,2021, 22: 6110.
[10] Li D, Liu F, Wang X, et al. Apple polyphenol extract alleviates high-fat-diet-induced hepatic steatosis in male C57BL/6 mice by targeting LKB1/AMPK pathway[J]. J Agric Food Chem,2019, 67: 12208–12218.
[11] Li D, Cui Y, Wang X, et al. Apple polyphenol extract improves high-fat diet-induced hepatic steatosis by regulating bile acid synthesis and gut microbiota in C57BL/6 male mice[J]. J Agric Food Chem, 2021, 69: 6829–6841.
[12] Li D, Cui Y, Wang X, et al. Apple polyphenol extract alleviates lipid accumulation in free-fatty-acid-exposed HepG2 cells via activating autophagy mediated by SIRT1/AMPK signaling[J]. Phytother Res,2021, 35: 1416–1431.
[13] Ding RB, Bao J, Deng CX.Emerging roles of SIRT1 in fatty liver diseases[J]. Int J Biol Sci,2017, 13: 852–867.
[14] Wang RH, Li C, Deng CX.Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition[J]. Int J Biol Sci,2010, 6: 682–690.
[15] Yan B, Chen L, Wang Y, et al. Preventive effect of apple polyphenol extract on high-fat diet-induced hepatic steatosis in mice through alleviating endoplasmic reticulum stress[J]. J Agric Food Chem,2022, 70: 3172–3180.
[16] 阮雄中, 陈压西. 代谢性炎症与非酒精性脂肪性肝病的发生与发展[J]. 中华消化杂志, 2020, 40: 581–584.
[17] Liu W, Cao H, Yan J, et al. 'Micro-managers' of hepatic lipid metabolism and NAFLD[J]. Wiley Interdiscip Rev RNA, 2015, 6: 581–593.
[18] 胡聪,吴琳静,熊印华,等. 脂质组学在肝脏疾病中的研究进展[J]. 中国药理学通报,2021,37: 6–12.
[19] Ooi GJ, Meikle PJ, Huynh K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis[J]. J Hepatol,2021, 75: 524–535.
[20] Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J].Cell Metab,2009, 9:327–338.
[21] Berlanga A, Guiu-Jurado E, Porras JA, et al. Molecular pathways in non-alcoholic fatty liver disease[J]. Clin Exp Gastroenterol,2014,7: 221–239.
[22] Béland-Bonenfant S, Rouland A, Petit JM, et al. Concise review of lipidomics in nonalcoholic fatty liver disease[J]. Diabetes Metab,2023, 49: 101432.
[23] Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk[J]. Adv Ther,2017, 34: 1291–1326.
[24] Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2021, 19: 61–71.e15.
[25] 彭晨芮,苗钟化,王一媚,等.高脂饮食诱导的内脏肥胖小鼠模型存在性别差异[J].浙江大学学报(医学版),2023,52: 117–125.
[26] Amirkalali B, Poustchi H, Keyvani H, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran[J]. Iran J Public Health, 2014, 43: 1275–1283.
[27] McGlinchey AJ, Govaere O, Geng D, et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease[J]. JHEP Rep,2022, 4: 100477.
[28] Zhu C, Huai Q, Zhang X, et al. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease[J]. Int J Biol Sci,2023, 19: 311–330.
[29] Sztolsztener K, Konstantynowicz-Nowicka K, Harasim-Symbor E, et al. Time-dependent changes in hepatic sphingolipid accumulation and PI3K/Akt/mTOR signaling pathway in a rat model of NAFLD[J]. Int J Mol Sci,2021, 22: 12478.